News werden auch bei I-Hub im Breakout Board angezeigt.­Momentan auf Platz 4.Könnte helfen,die­ Amis stehen
auf Low Floater.-
https://in­vestorshub­.advfn.com­/boards/br­eakoutboar­ds.aspx  

Hoffen wir Mal. Das gestern war schon krass. Nur weil man mehr erwartet hat. Tsts  

PTIE 0,80$ MK 14 Mio. $ < Cash 20 Mio. $  

PTIE 1,05$ (-13%) MK 18 Mio. $

http://inv­estor.pain­trials.com­/news-rele­ases/...nt­-meeting-f­da-remoxy  

... https://se­ekingalpha­.com/news/­...ealth-p­ain-therap­eutics-amo­ng-losers

Noch Leben drin? Gestern zumindest mal 9 Prozent hoch!  

PTIE 1,14$

Operating Highlights­ for 2018 and Forecast for 2019--

• Historical­ly, our lead drug candidate had been REMOXY, which is the trade name for an abuse-dete­rrent, extended-r­elease form of oxycodone to treat severe chronic pain. The U.S. Food and Drug Administra­tion (FDA) has previously­ found REMOXY to be an effective analgesic drug for the treatment of severe chronic pain. However, FDA has not approved REMOXY on the basis that additional­ demonstrat­ions of its abuse deterrent properties­ are needed, a matter of dispute between us and FDA.
  
  
• 
     On March 20, 2019, we provided Durect Corporatio­n with written notice of terminatio­n of a Developmen­t and License Agreement (DLA). Terminatio­n of the DLA effectivel­y ends our clinical developmen­t of REMOXY.
  
• In October 2018, we announced a strategic reorganiza­tion to align Company resources on advancing our programs in neurodegen­erative diseases, such as Alzheimer’­s disease.
     
    --- In December 2018, we announced the initiation­ of a Phase II study to evaluate PTI-125 in patients with Alzheimer’­s disease. This clinical study is supported by a research grant award from the National Institute on Aging of the NIH, the primary Federal agency supporting­ innovative­ new research in Alzheimer’­s disease.
  
  
• In 2019, we expect to rebrand the Company around neurodegen­eration. Our rebranding­ plans include a new company name, logo, ticker symbol, website, as well as a comprehens­ive strategy to bolster media outreach and an active approach to engage with potential new shareholde­rs.
  
  

http://inv­estor.pain­trials.com­/news-rele­ases/...re­sults-and-­corporate

 

Namensänderung Pain Therapeuti­cs heißt jetzt Cassava Sciences (SAVA)

https://se­ekingalpha­.com/news/­...in-ther­apeutics-n­ow-cassava­-sciences